Your browser doesn't support javascript.
loading
MED27, SLC6A7, and MPPE1 Variants in a Complex Neurodevelopmental Disorder with Severe Dystonia.
Reid, Kimberley M; Spaull, Robert; Salian, Smrithi; Barwick, Katy; Meyer, Esther; Zhen, Juan; Hirata, Hiromi; Sheipouri, Diba; Benkerroum, Hind; Gorman, Kathleen M; Papandreou, Apostolos; Simpson, Michael A; Hirano, Yoshinobu; Farabella, Irene; Topf, Maya; Grozeva, Detelina; Carss, Keren; Smith, Martin; Pall, Hardev; Lunt, Peter; De Gressi, Susanna; Kamsteeg, Erik-Jan; Haack, Tobias B; Carr, Lucinda; Guerreiro, Rita; Bras, Jose; Maher, Eamonn R; Scott, Richard H; Vandenberg, Robert J; Raymond, F Lucy; Chong, Wui K; Sudhakar, Sniya; Mankad, Kshitij; Reith, Maarten E; Campeau, Philippe M; Harvey, Robert J; Kurian, Manju A.
Afiliação
  • Reid KM; Molecular Neurosciences, Developmental Neurosciences, Zayed Centre for Research into Rare Disease in Children, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.
  • Spaull R; Molecular Neurosciences, Developmental Neurosciences, Zayed Centre for Research into Rare Disease in Children, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.
  • Salian S; Department of Neurology, Great Ormond Street Hospital, London, United Kingdom.
  • Barwick K; Department of Pediatrics, CHU Sainte-Justine Research Center, University of Montreal, Montreal, Quebec, Canada.
  • Meyer E; Molecular Neurosciences, Developmental Neurosciences, Zayed Centre for Research into Rare Disease in Children, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.
  • Zhen J; Molecular Neurosciences, Developmental Neurosciences, Zayed Centre for Research into Rare Disease in Children, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.
  • Hirata H; Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Sheipouri D; Department of Chemistry and Biological Science, College of Science and Engineering, Aoyama Gakuin University, Sagamihara, Japan.
  • Benkerroum H; School of Medical Sciences, University of Sydney, Sydney, New South Wales, Australia.
  • Gorman KM; Department of Pediatrics, CHU Sainte-Justine Research Center, University of Montreal, Montreal, Quebec, Canada.
  • Papandreou A; Department of Neurology and Clinical Neurophysiology, Children's Health Ireland at Temple Street, Dublin, Ireland.
  • Simpson MA; School of Medicine and Medical Sciences, University College Dublin, Dublin, Ireland.
  • Hirano Y; Molecular Neurosciences, Developmental Neurosciences, Zayed Centre for Research into Rare Disease in Children, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.
  • Farabella I; Department of Neurology, Great Ormond Street Hospital, London, United Kingdom.
  • Topf M; Division of Genetics and Molecular Medicine, King's College London School of Medicine, London, United Kingdom.
  • Grozeva D; Department of Chemistry and Biological Science, College of Science and Engineering, Aoyama Gakuin University, Sagamihara, Japan.
  • Carss K; Institute of Structural and Molecular Biology, Crystallography/Department of Biological Sciences, Birkbeck College, University of London, London, United Kingdom.
  • Smith M; CNAG-CRG, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
  • Pall H; Leibniz Institute for Virology (HPI) and Universitätsklinikum Hamburg Eppendorf (UKE), Centre for Structural Systems Biology (CSSB), Hamburg, Germany.
  • Lunt P; Institute of Structural and Molecular Biology, Crystallography/Department of Biological Sciences, Birkbeck College, University of London, London, United Kingdom.
  • De Gressi S; Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.
  • Kamsteeg EJ; Centre for Trials Research, Neuadd Meirionnydd, Cardiff University, Cardiff, United Kingdom.
  • Haack TB; Wellcome Trust Sanger Institute, Cambridge, United Kingdom.
  • Carr L; Department of Neurology, John Radcliffe Hospital, Oxford, United Kingdom.
  • Guerreiro R; Department of Neurology, Queen Elizabeth Hospital, Birmingham, United Kingdom.
  • Bras J; Clinical Genetic Service, Gloucester Royal Hospital, Gloucester, United Kingdom.
  • Maher ER; Department of Paediatrics, Cheltenham General Hospital, Gloucestershire, United Kingdom.
  • Scott RH; Department of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands.
  • Vandenberg RJ; Institute of Medical Genetics and Applied Genomics, University of Tuebingen, Tuebingen, Germany.
  • Raymond FL; Department of Neurology, Great Ormond Street Hospital, London, United Kingdom.
  • Chong WK; Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, Michigan, USA.
  • Sudhakar S; Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, Michigan, USA.
  • Mankad K; Department of Medical Genetics, University of Cambridge, Cambridge, United Kingdom.
  • Reith ME; Department of Clinical Genetics, Great Ormond Street Hospital, London, United Kingdom.
  • Campeau PM; School of Medical Sciences, University of Sydney, Sydney, New South Wales, Australia.
  • Harvey RJ; Centre for Trials Research, Neuadd Meirionnydd, Cardiff University, Cardiff, United Kingdom.
  • Kurian MA; Department of Radiology, Great Ormond Street Hospital, London, United Kingdom.
Mov Disord ; 37(10): 2139-2146, 2022 10.
Article em En | MEDLINE | ID: mdl-35876425
ABSTRACT

BACKGROUND:

Despite advances in next generation sequencing technologies, the identification of variants of uncertain significance (VUS) can often hinder definitive diagnosis in patients with complex neurodevelopmental disorders.

OBJECTIVE:

The objective of this study was to identify and characterize the underlying cause of disease in a family with two children with severe developmental delay associated with generalized dystonia and episodic status dystonicus, chorea, epilepsy, and cataracts.

METHODS:

Candidate genes identified by autozygosity mapping and whole-exome sequencing were characterized using cellular and vertebrate model systems.

RESULTS:

Homozygous variants were found in three candidate genes MED27, SLC6A7, and MPPE1. Although the patients had features of MED27-related disorder, the SLC6A7 and MPPE1 variants were functionally investigated. SLC6A7 variant in vitro overexpression caused decreased proline transport as a result of reduced cell-surface expression, and zebrafish knockdown of slc6a7 exhibited developmental delay and fragile motor neuron morphology that could not be rescued by L-proline transporter-G396S RNA. Lastly, patient fibroblasts displayed reduced cell-surface expression of glycophosphatidylinositol-anchored proteins linked to MPPE1 dysfunction.

CONCLUSIONS:

We report a family harboring a homozygous MED27 variant with additional loss-of-function SLC6A7 and MPPE1 gene variants, which potentially contribute to a blended phenotype caused by multilocus pathogenic variants. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Distúrbios Distônicos / Distonia / Transtornos do Neurodesenvolvimento / Transtornos dos Movimentos Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Animals Idioma: En Revista: Mov Disord Assunto da revista: NEUROLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Distúrbios Distônicos / Distonia / Transtornos do Neurodesenvolvimento / Transtornos dos Movimentos Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Animals Idioma: En Revista: Mov Disord Assunto da revista: NEUROLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido